CN109414490A - 抑制性免疫受体抑制方法和组合物 - Google Patents

抑制性免疫受体抑制方法和组合物 Download PDF

Info

Publication number
CN109414490A
CN109414490A CN201780039931.4A CN201780039931A CN109414490A CN 109414490 A CN109414490 A CN 109414490A CN 201780039931 A CN201780039931 A CN 201780039931A CN 109414490 A CN109414490 A CN 109414490A
Authority
CN
China
Prior art keywords
antibody
immunity receptor
inhibition
cell
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780039931.4A
Other languages
English (en)
Chinese (zh)
Inventor
埃利奥特·C·伍兹
肖涵
卡洛琳·R·贝尔托齐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN109414490A publication Critical patent/CN109414490A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780039931.4A 2016-07-01 2017-06-30 抑制性免疫受体抑制方法和组合物 Pending CN109414490A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357653P 2016-07-01 2016-07-01
US62/357,653 2016-07-01
PCT/US2017/040483 WO2018006066A1 (en) 2016-07-01 2017-06-30 Inhibitory immune receptor inhibition methods and compositions

Publications (1)

Publication Number Publication Date
CN109414490A true CN109414490A (zh) 2019-03-01

Family

ID=60787693

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780039931.4A Pending CN109414490A (zh) 2016-07-01 2017-06-30 抑制性免疫受体抑制方法和组合物

Country Status (7)

Country Link
US (2) US20190300606A1 (enExample)
EP (1) EP3478315A4 (enExample)
JP (1) JP2019527204A (enExample)
CN (1) CN109414490A (enExample)
AU (1) AU2017290884A1 (enExample)
CA (1) CA3026588A1 (enExample)
WO (1) WO2018006066A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114258431A (zh) * 2019-07-03 2022-03-29 帕利昂制药有限公司 重组人唾液酸酶、唾液酸酶融合蛋白及其使用方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7060502B2 (ja) 2015-10-29 2022-04-26 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－９抗体及びその使用方法
MX2019013648A (es) 2017-05-19 2021-01-08 Wuxi Biologics Shanghai Co Ltd Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).
MX2020007024A (es) 2018-01-03 2020-10-28 Palleon Pharmaceuticals Inc Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas.
WO2019200462A1 (en) * 2018-04-16 2019-10-24 Adaerata, Limited Partnership Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
WO2021003465A1 (en) * 2019-07-03 2021-01-07 Palleon Pharmaceuticals Inc. Sialidase-her2-antibody fusion proteins and methods of use thereof
CN114667298A (zh) 2019-11-04 2022-06-24 艾利妥 Siglec-9 ecd融合分子及其使用方法
US20230210841A1 (en) * 2020-05-15 2023-07-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compounds for inhibiting ly6k and methods of using same

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131453A1 (en) * 2008-04-23 2009-10-29 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system.
WO2015042246A1 (en) * 2013-09-20 2015-03-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
CN104645327A (zh) * 2003-07-24 2015-05-27 依奈特制药公司 使用nk细胞增效化合物提高治疗性抗体功效的方法和组合物
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
WO2015176033A1 (en) * 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2016025645A1 (en) * 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
WO2016033225A2 (en) * 2014-08-27 2016-03-03 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
WO2016038064A1 (en) * 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
US20160152720A1 (en) * 2014-11-06 2016-06-02 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104645327A (zh) * 2003-07-24 2015-05-27 依奈特制药公司 使用nk细胞增效化合物提高治疗性抗体功效的方法和组合物
WO2009131453A1 (en) * 2008-04-23 2009-10-29 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system.
WO2015042246A1 (en) * 2013-09-20 2015-03-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
WO2015176033A1 (en) * 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2016025645A1 (en) * 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
WO2016033225A2 (en) * 2014-08-27 2016-03-03 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
WO2016038064A1 (en) * 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
US20160152720A1 (en) * 2014-11-06 2016-06-02 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAMILLA JANDUS,ET AL: "Targeting Siglecs——A novel pharmacological strategy for immuno- and glycotherapy", 《BIOCHEMICAL PHARMACOLOGY》 *
陈子等: "肿瘤固有免疫的新靶点：唾液酸结合的免疫球蛋白样凝集素（Siglec)-7/9", 《中华临床医师杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114258431A (zh) * 2019-07-03 2022-03-29 帕利昂制药有限公司 重组人唾液酸酶、唾液酸酶融合蛋白及其使用方法

Also Published As

Publication number Publication date
US20190300606A1 (en) 2019-10-03
US20220169724A1 (en) 2022-06-02
JP2019527204A (ja) 2019-09-26
WO2018006066A1 (en) 2018-01-04
EP3478315A1 (en) 2019-05-08
CA3026588A1 (en) 2018-01-04
AU2017290884A1 (en) 2019-01-31
EP3478315A4 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
CN109414490A (zh) 抑制性免疫受体抑制方法和组合物
US10487150B2 (en) SIRP alpha-antibody fusion proteins
US20210277115A1 (en) Targeted therapy for small cell lung cancer
US10633450B2 (en) Methods for enhancing anti-tumor antibody therapy
CN109641038A (zh) 靶向细胞表面编辑的共轭物
CN109715666A (zh) 癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法
Leonard et al. Nonclinical safety evaluation of VX15/2503, a humanized IgG4 anti-SEMA4D antibody
Whipple et al. Analyses of the in vivo trafficking of stoichiometric doses of an anti-complement receptor 1/2 monoclonal antibody infused intravenously in mice
TW201739768A (zh) 新穎抗tnfrsf21抗體及使用方法
Baskar et al. Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells
Shaik et al. Monoclonal Antibodies in Clinical Trials for Breast Cancer Treatment
RU2800803C2 (ru) СТАБИЛЬНЫЕ КОМПОЗИЦИИ ИММУНОКОНЪЮГАТОВ, СОДЕРЖАЩИХ АНТИТЕЛО К CD79b
WO2023212632A2 (en) Anti-nucleophosmin 1 antibody and antibody conjugate combination therapies
Lindorfer How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca2+
HK1238573B (en) Sirp alpha-antibody fusion proteins
HK1238573A1 (en) Sirp alpha-antibody fusion proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190301

WD01 Invention patent application deemed withdrawn after publication